Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

In the 2010 Journal Citation Reports, The Lancet s impact factor was ranked second among general medical journals, at 33.63, after The New England Journal of Medicine (53.48). The Lancet also has ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

The full manuscript was subsequently published in The New England Journal of Medicine on January 22, 2025. The published results closely match the presentation. Find our full coverage below.

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...

Operator: Good day, and welcome to the Accuray Fiscal 2025 Second Quarter Financial Results Conference Call. All participants ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

Researchers have used AI to find adalimumab effective for iMCD, highlighting the potential of machine learning in discovering ...